Kohei shitara (@KoheiShitara) / X
Por um escritor misterioso
Descrição
Margherita Ambrosini (@margheambro1) / X
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Kohei shitara (@KoheiShitara) / X
OncologyTube - DESTINY-Gastric01 Phase II Study Kohei
Kohei shitara (@KoheiShitara) / X
Dr. Shitara on Zolbetuximab Plus mFOLFOX6 in CLDN18.2+, HER2– Gastric/GEJ Adenocarcinoma
Kohei SHITARA, Chief, Department of Gastrointestinal Oncolology
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Ravi Jaiswal, MD (@RaviJaiswal___) / X
de
por adulto (o preço varia de acordo com o tamanho do grupo)
